LivaNova PLC | Income Statement

Fiscal year is January-December. All values USD Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
254
282
624
965
1,012
1,107
Cost of Goods Sold (COGS) incl. D&A
23
29
224
436
394
410
Gross Income
232
253
400
528
618
697
SG&A Expense
152
166
337
435
491
606
EBIT
80
87
62
-
127
92
Unusual Expense
3
7
72
47
54
337
Non Operating Income/Expense
2
-
47
13
55
7
Interest Expense
-
-
2
10
9
10
Pretax Income
75
80
59
26
121
247
Income Tax
29
25
19
5
50
70
Equity in Affiliates
-
-
5
19
17
1
Consolidated Net Income
46
55
44
2
54
178
Net Income
46
55
44
2
54
178
Net Income After Extraordinaries
46
55
44
67
134
168
Net Income Available to Common
46
55
44
63
25
189
EPS (Basic)
1.66
2.00
1.36
1.28
0.52
3.91
Basic Shares Outstanding
28
27
33
49
48
48
EPS (Diluted)
1.66
2.00
1.36
1.29
0.52
3.91
Diluted Shares Outstanding
28
27
33
49
48
48
EBITDA
84
93
93
157
192
162
Non-Operating Interest Income
-
-
1
2
1
1

About LivaNova

View Profile
Address
20 Eastbourne Terrace
London Greater London W2 6LG
United Kingdom
Employees -
Website http://www.livanova.com
Updated 07/08/2019
LivaNova Plc is a global medical technology company, which engages in the development and delivery of important therapeutic solutions for the benefit of patients, healthcare professionals and healthcare systems. It operates through the Cardiac Surgery and Neuromodulation, and Other Corporate segments. The Cardiac Surgery and Neuromodulation segment corresponds to the primary therapeutic areas.